MTOR and autosomal dominant polycystic kidney disease: A meta-analysis of five randomized trials in patients with ADPKD reported that there was no significant difference in glomerular filtration rate (GFR) between the mTOR inhibitor-treated and control groups, while proteinuria was significantly higher in the treated group than in the control group.